Zofenopril plus hydrochlorothiazide: Combination therapy for the treatment of mild to moderate hypertension

Drugs

Volumn 66, Issue 8, 2006, Pages 1107-1115

  Zanchetti, Alberto ^a   Parati, Gianfranco ^b   Malacco, Ettore ^c  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF MILANO BICOCCA   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN II; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROCHLOROTHIAZIDE; ZOFENOPRIL;

BLOOD PRESSURE REGULATION; CLINICAL PRACTICE; CLINICAL TRIAL; COUGHING; DISEASE SEVERITY; DIZZINESS; DOSE RESPONSE; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; HEADACHE; HUMAN; HYPERTENSION; MONOTHERAPY; POLYURIA; PRACTICE GUIDELINE; REVIEW; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CAPTOPRIL; CLINICAL TRIALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; MALE; MIDDLE AGED;

EID: 33745415271     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200666080-00006     Document Type: Review

References (36)

1. Kearney PM, Whelton M, Reynolds K, et al. Global burden of hypertension: analysis of worldwide data. Lancet 2005; 365: 212-23
2. Kearney PM, Whelton M, Reynolds K, et al. Worldwide prevalence of hypertension: a systematic review. J Hypertens 2004; 22: 11-9
3. Wang TJ, Vasan RS. Epidemiology of uncontrolled hypertension in the United States. Circulation 2005; 112: 1651-62
4. Ezzati M, Lopez AD, Rodgers A, et al. Selected major risk factors and global and regional burden of disease. Lancet 2002; 360: 1347-60
5. Franklin S, Larson MG, Khan SA, et al. Does the relation of blood pressure to coronary heart disease risk change with aging? The Framingham Heart Study. Circulation 2001; 103: 1245-9
6. Vasan RS, Larson MG, Leip EP, et al. Impact of high-normal blood pressure on the risk of cardiovascular disease. N Engl J Med 2001; 345 (18): 1291-7
7. Collins R, MacMahon S. Blood pressure, antihypertensive drug treatment and the risks of stroke and of coronary heart disease. Br Med Bull 1994; 50: 272-98
8. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. Lancet 1998; 351: 1755-62
9. Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21: 1011-53
10. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood-pressure lowering regimens on major cardiovascular events: results of prospectively designed overviews of randomised trials. Lancet 2003; 362: 1527-35
11. National Heart, Lung and Blood Institute. The seventh report of the Joint National Committee on prevention, detection, evaluation and treatment of high blood pressure. NIH Publication No. 03- 5233, 2003 May
12. World Health Organization, International Society of Hypertension Writing Group. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens 2003; 21: 1983-92
13. Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000. JAMA 2003; 290 (2): 199-206
14. Hansson L, Zanchetti A, for the HOT Study Group. The Hypertension Optimal Treatment (HOT) study: 24-month data on blood pressure and tolerability. Blood Pressure 1997; 6: 313-7
15. Wetzels GEC, Nelemans P, Schouten JS, et al. Facts and fiction of poor compliance as a cause of inadequate blood pressure: a systematic review. J Hypertens 2004; 22: 1849-55
16. Moser M. Rationale for combination therapy in the management of hypertension. J Clin Hypertens 2003; 5 (6 Suppl. 4): 17-25
17. Zanchetti A. Contribution of fixed low-dose combinations to initial therapy in hypertension. Eur Heart J Suppl 1999; 1 Suppl. L: L5-9
18. Mancia G, Grassi G. Rationale for the use of a fixed dose combination in the treatment of hypertension. Eur Heart J Suppl 1999; 1 Suppl. L: L14-19
19. Mancia G, Zanchetti A, Agabiti-Rosei E, et al. Ambulatory blood pressure is superior to clinic blood pressure in predicting treatment-induced regression of left ventricular hypertrophy. Circulation 1997; 95: 1464-70
20. Lewis EJ, Hunsicker LG, Bain RP, et al. The effect of angiotensin-converting-enzyme therapy on diabetic nephropathy. N Engl J Med 1993; 329: 1456-62
21. Giatras I, Lau J, Levey AS, et al. Effect of angiotensin-converting- enzyme inhibitors on the progression of nondiabetic renal disease: a meta-analysis of randomized trials. Ann Intern Med 1997; 127 (5): 337-45
22. Zanchetti A, Ruilope LM. Antihypertensive treatment in patients with type-2 diabetes mellitus: what guidance from well controlled randomized trials? J Hypertens 2002; 20: 2095-110
23. Borghi C, Ambrosioni E. Zofenopril: a review of the evidence of its benefits in hypertension and acute myocardial infarction. Clin Drug Invest 2000; 20 (5): 371-84
24. Parati G, Omboni S, Malacco E, et al. Antihypertensive efficacy of zofenopril and hydrochlorothiazide combination on ambulatory blood pressure. Blood Pressure 2006; 15 Suppl. 1: 7-17
25. Malacco E, Omboni S. Antihypertensive efficacy of zofenopril plus hydrochlorothiazide fixed combination is superior to that of single components [abstract]. Eur Heart J 2005; 26: 401
26. Zozide prescribing information. Menarini International Operations Luxembourg S.A., 2005 Mar
27. Toto RD, Rinner S, Ram CVS. ACE inhibitors and target organ protection: an expanded role for these antihypertensive agents? Postgrad Med 2004; 116 (2): 11-6
28. Dzau V. The cardiovascular continuum and renin-angiotensin-aldosterone system blockade. J Hypertens 2005; 23 Suppl. 1: S9-17
29. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting- enzyme inhibitor, ramipril, on cardiovascular events in high risk patients. The Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. N Engl J Med 2000; 342 (3): 145-53
30. The EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 362: 782-8
31. Ambrosioni E, Borghi C, Magnani B, et al. The effect of the angiotensin-converting-enzyme inhibitor zofenopril on moragement tality and morbidity after anterior myocardial infarction. N Engl J Med 1995; 333: 80-5
32. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the Survival And Ventricular Enlargement trial. N Engl J Med 1992; 324: 669-77
33. SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992; 327: 685-91
34. Ferrari R, for the PREAMI Investigators. Effects of angiotensin- converting enzyme inhibition with perindopril on left ventricular remodeling and clinical outcome: results of the randomized Perindopril and Remodeling in Elderly with Acute Myocardial Infarction (PREAMI) study. Arch Intern Med 2006; 166: 659-66
35. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000; 355: 253-9
36. García-Estan J, Ortiz C, O'Valle F, et al. Effects of angiotensin converting enzyme inhibitors in combination with diuretics on blood pressure and renal injury in nitric oxide deficiency induced hypertension in rats. Clin Sci 2006; 110: 227-33